
News|Articles|March 1, 2007
First-time generic approvals
First-time generic approvals
Advertisement
First-time generic approvals
Valacyclovir tablets, 500 mg (base) and 1 g (base) (equiv to Valtrex caplets)
RANBAXY
Albuterol sulfate extended-release tablets, 4 mg (base) and 8 mg (base) (equiv to VoSpire ER tablets)
MYLAN
Fentanyl-12 transdermal system, 12.5 mcg/h (equiv to Duragesic-12)
MYLAN
Dexmethylphenidate tablets, 2.5, 5, and 10 mg (equiv to Focalin tablets)
TEVA
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sponsored: The Teva Biosimilars Trend Report
2
Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds
3
FDA Accepts NDA for Investigational Maintenance Asthma Treatment
4
The 6-Year Cure Threshold: Redefining Cure for Colon Cancer Survivors
5